Tim Revell shares his story on how him and his wife have been able to raise an exponential amount of money for the Duchenne community, through running marathons & connecting with big names from his alma mater.
@TexasExes@TexasLonghorns@MJMempowerkids
https://t.co/VLsfbTAlbX
Yesterday @USDOT@SecretaryPete announced plans for a new rule to allow passengers to stay in their wheelchairs when they fly. We're so excited to see our goal supported by so many people at the @USDOT
Happy Father's Day to all you amazing Dads! Especially John who will pull, push and carry Jake through an amazing life! We would also like to give a shout out to you Mom's and Grandparents doing double parenting duty. We salute you!
Just one month until 2022 FUTURES!
With ADA accessible rooms in our discounted room block still available, it's not too late to attend in person!
Register today: https://t.co/wxrMElcYl8
Join us via Zoom for The Benefit of #Corticosteroids on April 21st 11:00am PT/2:00pm ET, hosted by Dr. Aravindhan Veerapandiyan and Sheryl Marrazzo.
https://t.co/J1rTooW9fY
Join us for this informative webinar on CureDuchenne Link! Learn why Link was created, the ways it's being used for research, and how YOU can help accelerate the discovery of treatments for #Duchenne muscular dystrophy.
https://t.co/cOA8MkGVhX
Have you seen our speaker line-up?! Comment below and let us know who you’re looking forward to hearing from.
Attend in-person or virtually! Register today. + Travel assistance available.
https://t.co/xbMxwII54f
CALLING ALL GAMERS - join us in our e-Gaming Lounge at FUTURES. We can't wait to see you and your kids for this FUN, family-friendly conference that focuses on building community.
Register today: https://t.co/xbMxwII54f
In order to make our weekend-long conference feasible, CureDuchenne has secured a discounted room block, which includes ADA accessible rooms, at The JW Marriott Orlando, Grande Lakes.
Book your 2022 FUTURES hotel accommodations: https://t.co/2K14ViwxTC...
NS Pharma announced positive results today for a Phase I/II study evaluating the efficacy and safety of their exon 44 skipping drug (NS-089/NCNP-02) for #Duchenne. Read more information and the press release on our blog. https://t.co/0Gn1K0XOn1